23rd Belgian Congress on Rheumatology 2 - 4 October 2019

Final Programme

www.rheumacongress.be Table of Contents

Organisation...... 4

24th Belgian Congress on Rheumatology - BCR 2020...... 4

Welcome Address...... 5

Scientific Programme Wednesday, 2 October...... 6

Scientific Programme Thursday, 3 October...... 9

Scientific Programme Friday, 4 October...... 12

Meeting for Health Professionals in Rheumatology...... 14

Registration...... 16

General Information...... 17

Major Sponsors & Exhibitors...... 21

www.rheumacongress.be 3 Organisation Welcome Address

Scientific Organiser Maria Stoenoiu Cliniques universitaires Saint-Luc Dear colleagues and friends, Avenue Hippocrate 10, 1200 Bruxelles [email protected] The Royal Belgian Society for Rheumatology takes great pleasure in welcoming you to the 23rd Belgian Congress on Rheumatology, taking place in on Local Organising Committee 2- 4 October 2019. Veerle Taelman UZ Leuven The congress takes place at the University Hall of the KU Leuven. The Hall was Herestraat 49, 3000 Leuven originally built by the weavers to be used for trading fabric. The Fabric Hall is [email protected] currently the central place for student enrolment.

Margot Van We are proud to propose a varied and interesting programme with state-of-the- UZ Leuven art keynote lectures and oral communications. The ‘Year in Review’ will also be Herestraat 49, 3000 Leuven presented again, providing you with a survey of the Belgian publications of the [email protected] last year.

René Westhovens Furthermore, 2 poster tours, 4 workshops for early risers and 12 Updates in UZ Leuven Therapeutics are scheduled. The ‘Thieves Market’ is also scheduled again this Herestraat 49, 3000 Leuven year. [email protected] Together with the KBVR-SRBR Board members, we hope you will enjoy the Congress and the city of Leuven and remain, Upcoming Congress 24th Belgian Congress on Rheumatology - BCR 2020 Yours sincerely, 23 - 25 September 2020 Mons International Congress Xperience Prof. Maria Stoenoiu Scientific Organiser

Congress Secretariat Veerle Taelman, Margot Van Mechelen, René Westhovens Medicongress Services Local Organising Committee Noorwegenstraat 49 B-9940 Evergem, Phone: +32 (0)9 218 85 8 Fax: +32 (0)9 344 40 10 [email protected] MEDICONGRESS www.medicongress.com

4 www.rheumacongress.be www.rheumacongress.be 5 Wednesday, 2 October Wednesday, 2 October

Young Investigator Meeting Promotiezaal 12.30 Opening Ceremony Promotiezaal Chairs: Olivier Malaise (CHU de Liège, ULg) and Rik Lories (KU Leuven) Maria Stoenoiu, Scientific Organiser, Dirk Elewaut and Catherine Bailleux, KBVR-SRBR 10.00 Absence of MALT1 in T-cells protects against the development of auto- immune arthritis, but indirectly causes osteoporosis SESSION 1 Promotiezaal Elisabeth Gilis (UGent) Chairs: Pascale Volders (ReumaClinic Genk) and Patrick Verschueren (KU Leuven) 10.15 Detection of multiple myositis-specific autoantibodies with line and dot immunoassays in patients with idiopathic inflammatory 12.50 Vesalius Lecture myopathies Outcome measures in rheumatology, from trial to practice - How out Jean-Baptiste Vulsteke (KU Leuven) come measures have transformed rheumatology Maarten Boers (The Netherlands) 10.30 High disease activity impairs work participation and work productivity in spondyloarthritis patients Abstract Presentations Ann-Sophie De Craemer (UGent) 13.35 Seroreversion of autoantibodies to UH-RA.21 peptide is associated 10.45 Generation of an inducible tissue-specific DIO2 overexpression mouse with CDAI remission in rheumatoid arthritis patients of the CareRA Frederique Cornelis (KU Leuven) cohort Patrick Vandormael (Hasselt University) 11.00 Inhibition of Sphingosine 1 Phosphate protects chondrocyte catabolism and osteoarthritis 13.45 Comparison of transcriptomic profiles between paired joint biopsies Chahrazad Cherifi (KU Leuven) from Rheumatoid Arthritis patients Clément Triaille (UCL) 11.15 Hyperosmolar stress-induced osmoadaptative and inflammatory responses in human salivary glands cells 13.55 Enrichment of RORγt+ innate-like T cells in joint and gut samples from Clara Chivasso (ULB) spondyloarthritis patients Céline Mortier (UGent) 11.30 Identification of transcription factors and networks regulating the DOT1L gene FWRO/FRSR Award Ceremony Astrid De Roover (KU Leuven) 14.05 René Westhovens (KU Leuven) and Philippe Carron (UGent)

ANP32A deficiency partially protects against bleomycin-induced skin 11.45 Update in Therapeutics – Organised with an educational grant from Sanofi fibrosis 14.30 Nathalie Berghen (KU Leuven) Why does clinical practice not always reflect clinical guidelines? Robert Landewé (The Netherlands) 12.00 Welcome Lunch in the Exhibition Hall 15.00 Update in Therapeutics – Organised with an educational grant from Amgen The value of treatment monitoring and targeting in chronic rheumatic diseases Tore Kvien (Norway)

15.30 Coffee Break in the Exhibition Hall

6 www.rheumacongress.be www.rheumacongress.be 7 Wednesday, 2 October Thursday, 3 October

SESSION 2 Promotiezaal 08.00 Workshop 1 Room Franciscanen Chairs: Alla Ishchenko Alla Ishchenko (ZNA Jan Palfijn, Middelheim Evaluation and management of psoriatic arthritis and psoriasis Hospital, UZ Gasthuisberg, KU Leuven) and Kurt de Vlam (KU Leuven) and Adrien Nzeusseu Toukap (UCL) Kurt de Vlam (KU Leuven) Workshop 2 Room Dominicanen 16.00 Treatment of Sjogren’s disease – State-of-the-Art Autoantibodies in clinical practice Isabelle Peene (AZ Sint-Jan) Ellen De Langhe (KU Leuven) and Xavier Bossuyt (KU Leuven) 16.30 The hunt for the wolf: Shaping the treatment of SLE Farah Tamirou (UCL) The Workshops take place at Hotel Martin’s Klooster, O.L.Vrouwstraat 18 (located at 450 m from the University Hall). 17.00 Update in Therapeutics – Organised with an educational grant from Roche Rituximab in auto-immune diseases Ellen De Langhe (KU Leuven) SESSION 4 Promotiezaal Chairs: Silvana Di Romana (CHU St. Pierre) and Vanessa Smith (UGent) 17.30 Update in Therapeutics – Organised with an educational grant from AbbVie Comorbidities management in spondyloarthritis Abstract Presentations Anna Molto (France)

18.00 Walking Dinner in the Exhibition Hall 09.00 Maintaining remission in patients with rheumatoid arthritis while tapering etanercept: The TapERA trial Delphine Bertrand (KU Leuven) SESSION 3 - Ethics & Economy Promotiezaal Chairs: Margot van Mechelen (KU Leuven), Veerle Taelman (KU Leuven) 09.10 Fast Track algorithm: How to differentiate a ‘scleroderma pattern’ and René Westhovens (KU Leuven) from a ‘non-scleroderma’ pattern Vanessa Smith (UGent) 19.30 Health professionals: Current and future projects Overview of the organization of Belgium’s healthcare First data of the TARDIS-RA registry, a nationwide Belgian Biologic Caroline Teugels, International Federation of Podiatrists 09.20 registry Diederik De Cock (KU Leuven) 19.45 Patient associations: Current and future activities How to increase visibility and awareness Gerd Jacobs, ReumaNet and Alain Cornet, CLAIR 09.30 Cardiovascular comorbidities in rheumatic diseases 20.00 BRV-AMRB update and future projects - Organisation of healthcare in Anne Grete Semb (Norway) Belgium Laurent Méric de Bellefon (CNDG, CHU Saint-Pierre Brussels, UCL) and 10.15 Year in Review – Clinical and basic science Ilse Hoffman (GZA, AZ Sint Jozef) Béatrice André (CHU de Liège, ULg) and Shan Soyfoo (ULB) 20.30 The bionic patient: Consumer technology including wearables changing clinical practice 10.45 Coffee Break in the Exhibition Hall Will Dixon (United Kingdom) and Thijs Swinnen (KU Leuven) 11.00 Poster Tour 1 in the Exhibition Hall 21.30 Panel Discussion Poster Tour Leaders: Peggy Jacques (UGent) and Patrick Verschueren (KU Leuven) 22.30 End of Day 1 Poster presenters are invited to be available for Q&A

8 www.rheumacongress.be www.rheumacongress.be 9 Thursday, 3 October Thursday, 3 October

SESSION 5 Promotiezaal SESSION 7 Promotiezaal Chairs: Charline Rinkin (CHU de Liège, ULg) and Rik Lories (KU Leuven) Chairs: Laure Tant (ULB) and Filip Van den Bosch (UGent)

11.30 Update in Therapeutics – Organised with an educational grant from Eli Lilly Abstract Presentations Small molecules will change rheumatology - Update on JAKs/kinase inhibition 16.20 Predictors of radiographic progression in hand osteoarthritis: Daniel Aletaha (Germany) A ten-years prospective cohort study Tine Vanhaverbeke (UGent) 12.00 Update in Therapeutics – Organised with an educational grant from BMS Biomarkers: What can we learn from immuno-oncology? 16.30 Predictors of functional progression in hand osteoarthritis: Karim Vermaelen (UGent) A ten-years prospective cohort study Lisa Pardaens (UGent) 12.30 SpA: State-of-the-art diagnosis and treatment of peripheral spondylo- arthritis - Worth the attention? 16.40 In-hospital screening is more effective than ambulatory practice Philippe Carron (UGent) screening to detect osteoporosis: A 6-year study in 6406 patients Olivier Malaise (ULg) 13.00 Lunch in the Exhibition Hall 16.50 Update in Therapeutics – Organised with an educational grant from 14.00 General Assembly Novartis New insights in the pathogenesis of spondyloarthritis Dirk Elewaut (UGent) SESSION 6 Promotiezaal Update in Therapeutics – Organised with an educational grant from Chairs: Maria-José Fernandez (UZA, Medicis, OLV Aalst) and 17.20 Galapagos Ruth Wittoek (UGent, ZNA Jan Palfijn) How digital technologies enable the global transformation of 14.15 Update in Therapeutics – Organised with an educational grant from MSD healthcare Imaging in the diagnosis and treatment of axial spondylarthropathies Geert Reyniers (Duval Union Consulting) Xenofon Baraliakos (Germany) 17.50 End of Day 2 14.45 Update in Therapeutics – Organised with an educational grant from Biogen How should biosimilars be used to treat rheumatic diseases? Alfons den Broeder (The Netherlands)

15.15 The power and pitfalls of musculoskeletal ultrasound in daily practice Maria Stoenoiu (UCL)

15.50 Coffee Break in the Exhibition Hall

10 www.rheumacongress.be www.rheumacongress.be 11 Friday, 4 October Friday, 4 October

08.00 Workshop 3 Room Dominicanen 11.00 Coffee Break in the Exhibition Hall Ultrasound hands-on: Ankle Philippe Carron (UGent), Alla Ishchenko (ZNA Jan Palfijn, Middelheim 11.15 Poster Tour 2 in the Exhibition Hall Hospital, UZ Gasthuisberg, KU Leuven), Maria-José Fernandez (UZA, Poster Tour Leaders: Silvia Monteagudo (KU Leuven) and Medicis, OLV Aalst), Marie Joelle Kaiser (Ulg), Ruth Wittoek (UGent, Olivier Malaise (CHU de Liège, ULg) ZNA Jan Palfijn), Maria Stoenoiu (UCL) Poster presenters are invited to be available for Q&A

Workshop 4 Room Predikheren 11.45 Bone and Joint Lecture Promotiezaal Axial MRI interpretation Rheumatoid arthritis, yesterday and tomorrow Lennart Jans and Peggy Jacques (UGent) René Westhovens (KU Leuven)

The Workshops take place at Hotel Martin’s Klooster, O.L.Vrouwstraat 18 (located at 450 m from the University Hall). SESSION 9 Promotiezaal Chairs: Bouchra Lechkar (UZA) and Xavier Janssens (AZ Sint-Lucas, UGent) SESSION 8 Promotiezaal Chairs: Olivier Malaise (CHU de Liège, ULg) and Thieves Market Ilse Hoffman (GZA Sint-Augustinus, Wilrijk) 12.15 A novel phenotype of adult-onset autoinflammatory syndrome 09.00 The future treatments of OA caused by somatic NLRC4 mosaicism Rik Lories (KU Leuven) Nathalie Berghen (KU Leuven)

Abstract Presentations 12.25 Fulminant macrophage activation syndrome in a patient with anti- synthetase syndrome successfully treated with etoposide 09.30 Gender contrasts in patient reported outcomes do not alter the Friedel Vulsteke (KU Leuven) disease activity score in axial spondyloarthritis patients Ann-Sophie De Craemer (UGent) 12.35 Multiple vertebral fractures after bone marrow transplantation in a young patient with sickle cell disease? When DEXA misleads us 09.40 High prevalence of sacroiliac bone marrow edema on MRI in postpartum Marine Mina (ULg) women: A temporary phenomenon Thomas Renson (UGent) 12.45 Closure of the Congress

09.50 ANP32A is a hub molecule regulating a protective network against 13.00 Farewell Lunch osteoarthritis Silvia Monteagudo (KU Leuven) 13.45 KBVR-SRBR Board Meeting Room Predikheren, Hotel Martin’s Klooster 10.00 Update in Therapeutics – Organised with an educational grant from Celgene Management of psoriatic arthritis from the view of the dermatologist Diamant Thaçi (Germany)

10.30 Update in Therapeutics – Organised with an educational grant from Pfizer Pain and other outcomes in patients treated with JAK/STAT inhibitors Ernest Choy (United Kingdom)

12 www.rheumacongress.be www.rheumacongress.be 13 Thursday, 3 October Thursday, 3 October

Meeting for Health Professionals in Rheumatology – Morning Meeting for Health Professionals in Rheumatology – Afternoon Chairpersons: Kristien Van der Elst ( UZ Leuven) and Elli Sydow (UZ Leuven) 13.30 General Assembly BeHPR 08.30 Registration* Welcome and a must-do for all

09.00 Welcome Chairpersons: Laura Lepers (Erasme ULB) and Chantal Robert (Erasme ULB) Karlien Claes, MSc rheumatology nurse, Ghent University Hospital President of the Belgian Health Professionals in Rheumatology 14.20 New insights in the management of Spondylarthropathy Adrien Nzeusseu, Prof. Dr., Rheumatology department, St-Luc University A peek into the everyday life of children and young people with hospital, Experimental and Clinical Research Institutes, UC Louvain, rheumatic conditions Brussels

09.10 Juvenile rheumatic diseases and therapies 14.40 Belgian Inflammatory Arthritis and Spondylitis Cohorte (Be-Giant) Joke Dehoorne, PhD, pediatrician, department of Rheumatology, Thomas Renson, PhD candidate, pediatrician, department of Rheumatology, Sint-Elisabeth Hospital/Ghent University Hospital Sint-Elisabeth Hospital/ Ghent University Hospital Lien De Somer, PhD, pediatrician, department of Rheumatology, University Hospital Leuven 15.00 Abstract 1: A mixed method study to explore the feasibility and patient satisfaction of two different exercise programs in systemic sclerosis 09.45 What does it mean to grow up with juvenile idiopathic arthritis? associated microstomia A patient’s view Ellinor Sydow, MSc Occupational therapist, University Hospital Leuven

10.00 Young people in pediatric and adult rheumatology: Who cares? 15.10 Coffee break Margot Walter, PhD, Nurse specialist in Rheumatology, Erasmus MC, Rotterdam Chairpersons: Caroline Teugels (Executive Director of the International Federation of Podiatrists) and 10.30 Coffee break Karlien Claes (Ghent University Hospital)

Chairpersons: Aleksandra Avramosvka (UC Louvain) and 15.40 Abstract 2: Why doing "CardioPulmonaryExerciseTesting" for Karlien Claes (Ghent University Hospital) Rheumatoid Arthritis patients is important Chantal Robert, physiotherapist, University Hospital Brussels 11.00 How to treat locomotor impairments in children with a rheumatic disease? 15.50 The added value of a physiotherapist in people with a rheumatic disorder Ruth Van der Looven, MD, PhD, physiatrist, department of physical Dieter Van Assche, Physical therapist at division of rheumatology University medicine and child rehabilitation, Ghent University Hospital Hospitals Leuven and assistant professor at department of rehabilitation sciences KU Leuven 11.30 What is the added value of a psychologist in the management of children with JIA 16.20 Workshop: The benefits of a good sport shoe Joanna Willen, psychologist, University Hospital Leuven 16.50 Closing 12.00 What does it mean to grow up with juvenile idiopathic arthritis? A patient’s view The Meeting for Health Professionals in Rheumatology takes place at 12.15 Lunch Break & Networking Room Predikheren, Hotel Martin’s Klooster.

*Registration includes coffee breaks and lunch.

14 www.rheumacongress.be www.rheumacongress.be 15 Registration General Information

Registration Fees LATE As of 1 September Venues Members KBVR-SRBR € 250,00 University Hall KU Leuven Non Members € 350,00 Naamsestraat 22 Trainees in Rheumatology* € 75,00 3000 Leuen Other Trainees* € 100,00 Researchers non-MD* € 75,00 The Workshops take place in at Hotel Martin’s Klooster, O.L.Vrouwstraat 18 Emeriti € 75,00 (located at 450 m from the Universiteitshallen). Workshops** Free

Healthcare Professionals Meeting Free on Thursday 03/10

* Registration as a trainee or researcher non-MD will only be accepted if accompanied by a copy of your student card or a certificate of your director. Without proof the non- member fee will be charged. ** Participation in the workshops is free of charge and is limited to 30 participants.

The registration fee for participants includes • Participation in all scientific sessions • Participation in the hands-on workshops (separate registration required, limited to 30 participants) • Participation in the ‘Updates in Therapeutics’ organised by the Industry • Congress bag with the Programme and Abstracts and congress related documents • Access to the exhibition • Lunches and coffee breaks Accreditation A request for accreditation has been submitted to the RIZIV/INAMI. A certificate of attendance will be sent by email after the Congress. Cancellations Please make sure to sign the attendance list each day at the KBVR-SRBR booth. Participants canceling their registration before 1 September 2019, will receive a full refund, less € 50,00 administration costs. There will be no refunds for cancellations received after this date. Cancellations must be confirmed in writing Exhibition to the Organising Secretariat. All refunds will be processed after the Congress. A medical exhibition will be held on the occasion of the Congress. Access is free for registered participants. The exhibition is not accessible for non-MDs.

Liability Neither the organisers nor Medicongress accept liability for damages and/or losses of any kind which may be incurred by Congress participants during the Congress. Participants are advised to take out insurance against loss, accidents or damage which could be incurred during the Congress.

16 www.rheumacongress.be www.rheumacongress.be 17 Notes Notes

18 www.rheumacongress.be www.rheumacongress.be 19 Notes Major Sponsors

20 www.rheumacongress.be www.rheumacongress.be 21 The Organising Committee of the 23rd Belgian Congress on Rheumatology would like to thank

Major Sponsors AbbVie Amgen Biogen Belgium Bristol-Myers Squibb Celgene Eli Lilly Galapagos MSD Belgium Novartis Pharma Pfizer Roche Sanofi

Exhibitors AbbVie BK Medical Benelux Fresenius-Kabi GE Healthcare Grünenthal Lamepro Mylan Tilman TRB Chemedica UCB Pharma

Sandoz_1909_adv_A5.indd 1 09/09/2019 16:36 FOR ANKYLOSING SPONDYLITIS P.P. Co-payment* AND PSORIATIC ARTHRITIS Cosentyx® 2x150 mg € 1.059,78 € 12,10 Cosentyx® 1x150 mg € 565,09 € 12,10 WATCH ME IMPROVE AND MOVE MOBILITY TODAY AND TOMORROW

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See full leaflet for how to report adverse reactions. Name: Cosentyx 150 mg solution for injection in pre-filled syringe / Cosentyx 150 mg solution for injection in pre-filled pen Composition: Each pre-filled syringe contains 150 mg secukinumab* in 1 ml / Each pre-filled pen contains 150 mg secukinumab* in 1 ml. * Secukinumab is a recombinant fully human monoclonal antibody selective for interleukin-17A. Secukinumab is of the IgG1/κ-class produced in Chinese Hamster Ovary (CHO) cells. For the full list of excipients, see full leaflet. Pharmaceutical form: Solution for injection in pre-filled syringe (injection). The solution is clear and colourless to slightly yellow / Solution for injection in pre-filled pen (SensoReady pen). The solution is clear and colourless to slightly yellow. Therapeutic indications: Plaque psoriasis: Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Psoriatic arthritis: Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease- modifying anti-rheumatic drug (DMARD) therapy has been inadequate. Ankylosing spondylitis: Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. Posology: Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated. Plaque psoriasis. The recommended dose is 300 mg of secukinumab by subcutaneous injection with initial dosing at Weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Each 300 mg dose is given as two subcutaneous injections of 150 mg. Psoriatic arthritis. For patients with concomitant moderate to severe plaque psoriasis or who are anti-TNFα inadequate responders (IR), the recommended dose is 300 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Each 300 mg dose is given as two subcutaneous injections of 150 mg.For other patients, the recommended dose is 150 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Based on clinical response, the dose can be increased to 300 mg. Ankylosing spondylitis. The recommended dose is 150 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. For all of the above indications, available data suggest that a clinical response is usually achieved within 16 weeks of treatment. Consideration should be given to discontinuing treatment in patients who have shown no response by 16 weeks of treatment. Some patients with an initial partial response may subsequently improve with continued treatment beyond 16 weeks. Special populations: Elderly patients (aged 65 years and over): No dose adjustment is required. Renal impairment / hepatic impairment: Cosentyx has not been studied in these patient populations. No dose recommendations can be made. Paedriatic population: The safety and efficacy of Cosentyx in children below the age of 18 years have not yet been established. No data are available. Contraindications: Severe hypersensitivity reactions to the active substance or to any of the excipients. Clinically important, active infection (e.g. active tuberculosis). Undesirable effects: Summary of the safety profile: see full leaflet. List of adverse reactions: ADRs from psoriasis, psoriatic arthritis and ankylosing spondylitis clinical studies as well as from post-marketing experience (Table 1) are listed by MedDRA system organ class. Within each system organ class, the ADRs are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); and not known (cannot be estimated from the available data).List of adverse reactions in clinical studies1) and post-marketing experience: Infections and infestations: Very common: Upper respiratory tract infections; Common: Oral herpes; Uncommon: Oral candidiasis; Uncommon: Tinea pedis; Uncommon: Otitis externa. Not known: Mucosal and cutaneous candidiasis (including oesophageal candidiasis). Blood and lymphatic system disorders: Uncommon: Neutropenia. Immune system disorder: Rare: Anaphylactic reactions. Eye disorders: Uncommon: Conjunctivitis. Respiratory, thoracic and mediastinal disorders: Common: Rhinorrhoea. Gastrointestinal disorders: Common: Diarrhoea. Skin and subcutaneous tissue disorders: Uncommon: Urticaria. 1)Placebo-controlled clinical studies (phase III) in plaque psoriasis, PsA and AS patients exposed to 300 mg, 150 mg or placebo up to 12 weeks (psoriasis) or 16 weeks (PsA and AS) treatment duration. Description of selected adverse reactions: see full leaflet. Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Mode of delivery: Medicinal product subject to medical prescription. Marketing authorisation holder and numbers: Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland; EU/1/14/980/001- EU/1/14/980/007 Date of revision of the text: 23.10.2018

* ordinary insured persons (preferentially insured persons € 8,00) BE1903986436-26/03/2019

Cosentyx_SpA_Pub_A5.indd 1 20/09/2019 9:56:27